(Breast Cancer) Is Patritumab Deruxtecan Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
From June 3–7, 2022, Dr. Ian E. Krop and colleagues from the Dana-Farber Cancer Institute presented results at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on the efficacy and safety of patritumab deruxtecan in the U31402-A-J101 Phase 1/2 clinical trial in previously treated HER3-positive metastatic breast cancer patients.
The U31402-A-J101 Phase 1/2 trial was an open-label, multi-center study. An initial dose-escalation phase enrolled 66 patients with HER3-positive metastatic breast cancer and evaluated the safety, tolerability, and maximum tolerated dose of patritumab deruxtecan on a 3-week cycle. Subsequent dose-expansion cohorts enrolled different patient subtypes at the following doses:
- HER3 high-expressing group: 4.8 mg/kg (N=66) and 6.4 mg/kg (N=31)
- HER3 low-expressing group: 6.4 mg/kg (N=21)
- HR+/HER2−, triple-negative, and HER3 high-expressing: 6.4 mg/kg (N=31)
Patient characteristics: median age 57 years (range: 30–83), ECOG PS 0 in 72.5% (N=132) and ECOG PS 1 in 27.5% (N=50), median prior therapies: 5 (range: 1–13).
At a median follow-up of 31.9 months, objective response rates (ORR) were:
- HR+/HER2−, HER3 high+low expressing: 30.1% (N=113)
- Triple-negative breast cancer, HER3 high-expressing: 22.6% (N=53)
- HER2-positive, HER3 high-expressing: 42.9% (N=14)
Median duration of response was:
- HR+/HER2−, HER3 high+low expressing: 7.2 months
- Triple-negative, HER3 high-expressing: 5.9 months
- HER2-positive, HER3 high-expressing: 8.3 months
Safety: Grade 3 or higher adverse events occurred in 71.4% (N=130). Adverse events occurring in ≥15% of patients included: neutropenia (39.6%), thrombocytopenia (30.8%), anemia (18.7%), and leukopenia (18.1%). Treatment-related interstitial lung disease was observed in 6.6% (N=12), including one Grade 5 event.
Conclusion: Based on U31402-A-J101 trial results, Dr. Krop and colleagues concluded that patritumab deruxtecan demonstrated meaningful anti-tumor activity with manageable tolerability in previously treated HER3-positive metastatic breast cancer patients across triple-negative, HR+/HER2−, and HER2-positive subtypes.
Source: https://meetings.asco.org/abstracts-presentations/206936
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1